# Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

> **NCT03747497** · PHASE2 · COMPLETED · sponsor: **MicuRx** · enrollment: 196 (actual)

## Conditions studied

- Skin Diseases, Bacterial
- Gram-Positive Bacterial Infections

## Interventions

- **DRUG:** contezolid acefosamil
- **DRUG:** linezolid 600 mg

## Key facts

- **NCT ID:** NCT03747497
- **Lead sponsor:** MicuRx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-15
- **Primary completion:** 2019-03-26
- **Final completion:** 2019-03-26
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03747497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03747497, "Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03747497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*